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E-mail address: oliver.hanemann@pms.ac.uk (C.O.Recent evidence suggests that the neuroﬁbromatosis type 2 (NF2) gene encoded protein merlin sup-
presses mitogenic signalling not only at the cell membrane but also in the nucleus. At the mem-
brane, merlin inhibits signalling by integrins and tyrosine receptor kinases (RTKs) and the
activation of downstream pathways, including the Ras/Raf/MEK/ERK, FAK/Src, PI3K/AKT, Rac/PAK/
JNK, mTORC1, andWnt/b-catenin pathways. In the nucleus, merlin suppresses the E3 ubiquitin ligase
CRL4DCAF1 to inhibit proliferation. Gene expression analysis suggested that CRL4DCAF1 could also reg-
ulate the expression of integrins and RTKs. In this review, we explore the links between merlin func-
tion at the membrane and in the nucleus, and discuss the potential of targeting the master regulator
CRL4 DCAF1 to treat NF2 and other merlin-deﬁcient tumours.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.1. Introduction
Merlin (also known as schwannomin) is encoded by the neuro-
ﬁbromatosis type 2 (NF2) gene [1,2] and is a tumour suppressor.
Mutations in the NF2 gene, leading to loss of merlin protein, cause
nervous system tumours, including schwannomas, meningiomas
and ependymomas, which are part of the autosomal dominant
familiar cancer syndrome NF2. Biallelic NF2 mutations are also
responsible for all spontaneous schwannomas, 50–60% of sponta-
neous meningiomas and 20–30% of ependymomas. In addition, loss
of merlin is associated with other cancers, e.g. malignant mesothe-
liomas [3], glioblastomas [4,5], and has recently been linked to
breast cancer [6].
Merlin/NF2 shows high homology to the ERM (Ezrin-Radixin-
Moesin) family [1,2]. Like other ERM proteins, merlin protein con-
sists of an N-terminal FERM domain, a coil–coil segment followed
by a C-terminal domain. Unlike other ERM proteins, merlin lacks
the canonical actin-binding motif at its C-terminus, it interacts
with the actin cytoskeleton through a actin-binding domain at its
N-terminus [7]. Merlin has long been considered as a tumour sup-
pressor regulating signalling at the membrane and cortex of cell
[8]. At the membrane, merlin regulates expression and activation
of integrins and tyrosine receptor kinases (RTKs) and the activation
of downstream pathways, including the Ras/Raf/MEK/ERK, FAK/Src,
PI3K/AKT, Rac/PAK/JNK, mTORC1 and Wnt/b-catenin pathways.cal Societies. Published by Elsevier
iology, Peninsula College of
e John Bull Building, Tamar
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Hanemann).Recent evidence suggests that merlin suppresses mitogenic signal-
ling not only at the cell membrane but also in the nucleus [9]. In
the nucleus, merlin suppresses the E3 ubiquitin ligase CRL4DCAF1
to inhibit proliferation. This review focuses on merlin suppression
of the E3 ubiquitin ligase CRL4DCAF1 and tries to link merlin’s func-
tion in the nucleus and at the membrane. We start with a short
description of merlin’s functions at the membrane and concentrate
on those which can be linked to CRL4DCAF1. We then describe mer-
lin’s function in the nucleus via CRL4DCAF1. Finally we discuss the
potential therapeutic strategies for NF2 and other merlin-deﬁcient
tumours.
2. At the membrane, merlin inhibits integrins and RTKs
mediated mitogenic/survival signalling
2.1. Integrins and related the Rac/PAK/JNK, FAK/Src and mTORC1
pathways
The interaction between merlin and integrins was revealed in
isolated and differentiated Schwann cells [10]. Loss ofmerlin in sch-
wannomas leads to pathological adhesion [11,12]. Utermark et al.
[12] showed that the enhanced adhesion is linked to increased
expression of integrins a6, b1 and b4 at protein level and mRNA le-
vel. The upregulation of integrins a6, b1 and b4was conﬁrmed in an
array analysis when mRNA from schwannomas was compared to
Schwann cells [13]. Further activation of integrin has been linked
tomerlin deﬁciency [14,15]. Indeed, knockdown of integrin b1 with
lentiviral shRNA in human schwannoma cells decreased the prolif-
eration and adhesion upon IGFBP stimulation [14].B.V. Open access under CC BY-NC-ND license.
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cellular matrix, small GTPases Rac1 and Cdc42 are recruited to
the membrane. This in turn activates its effectors p21 activated
kinases (PAKs) and then downstream protein c-Jun N-terminal
kinase (JNK). Interestingly, PAK1/2 are actually the kinases which
can phosphorylate merlin at S518 [16,17]. This change of phos-
phorylation status of merlin switches it into a probable inactive
state. Extensive research in different cell models suggests that
merlin suppresses the Rac/PAK/JNK pathway [18–22]. Therefore,
an activation loop between merlin and PAK was suggested [21]
and merlin loss would lead to activation of the small GTPases at
the membrane [11,23,24].
In addition to Rac/PAK/JNK, integrins can regulate Focal adhe-
sion kinase (FAK) and its binding partner Src. FAK, a non-receptor
tyrosine kinase localised predominantly to the site of focal adhe-
sion, plays a central role in cell adhesion and migration [25].
Increased expression of FAK has been correlated with many types
of cancers, including brain, breast, prostate and colon [26–29].
Indeed, FAK plays a critical role in cancer initiation and progression
[30]. Proto-oncogene non-receptor tyrosine kinase Src and FAK,
can form a dual kinase complex which phosphorylates many adap-
tor proteins including merlin binding partner Paxillin [31]. Due to
their activation in many tumours FAK/Src are considered as prom-
ising therapeutic targets [32]. In NF2/ (merlin null) tumours cells
it has also been shown that FAK functions upstream of PI3K/AKT
and Raf/MEK/ERK pathways to potentiate schwannoma prolifera-
tion, migration and cell survival [14,33,34]. In mouse embryonic
ﬁbroblasts (MEFs), it has been shown that FAK phosphorylation
at Tyr397, which is an auto-phosphorylation site triggered by inte-
grin, and FAK’s connections with Src and PI3K are tightly regulated
by merlin’s expression [34]. It has been described that activated Src
recruits FAK and Paxillin in NF2/ mouse astrocyte cells [35]. In
addition, both Src activity (Y416) and FAK phosphorylation at
Y397 and Y925 (Src phosphorylation site) are signiﬁcantly in-
creased in schwannoma cells compared with Schwann cells
[14,33]. Thus FAK/Src are activated downstream of integrins after
merlin loss. RNA interference experiments have conﬁrmed that
integrin b1 directly functions upstream of FAK, as knockdown of
integrin b1 completely abolished IGFBP1 (acting via integrin alpha
5) mediated FAK phosphorylation/activity at Y397 in human
schwannoma cells [14]. Furthermore, the nuclear localisation of
FAK in schwannoma cells suggests its regulation of proliferation
in the cells without merlin [14].
To potentiate cell cycle progression at G1, integrins can promote
activation of mTORC1 and then cyclin D1 in merlin-deﬁcient malig-
nant mesothelioma cells [15]. The activation of mTOR is linked to
the increased survival in above mentioned merlin-deﬁcient cells.
Using the same experimental setting, López-Lago et al. also demon-
strated that ﬁrstly merlin negative cells are sensitive to the mTOR
inhibitor rapamycin, secondly re-introduction of merlin reduces
the sensitivity to rapamycin and thirdly depletion of merlin
restored the sensitivity to rapamycin in merlin positive mesotheli-
oma cell lines [15]. Evidence of merlin regulating mTORC1 was also
found in primary meningioma and schwannoma cells [36].
Thus as discussed above, integrins and downstream pathways
are responsible for the pathological cell–matrix adhesion and
increased proliferation in merlin-deﬁcient tumours. However, inte-
grins do not work on their own [37,38]. In merlin deﬁcient tu-
mours, in concert with integrins, receptor tyrosine kinases (RTKs)
are also activated [33,39].
2.2. RTKs and related Ras/Raf/MEK/ERK, PI3K/AKT, FAK/Src and Rac/
PAK/JNK
Emerging data suggest that there are at least four types of RTK
involved in merlin-deﬁcient tumours: ErbB receptors, platelet-derived growth factor receptor (PDGFR), insulin-like growth factor
1 receptor (IGF1R), and vascular endothelial growth factor recep-
tors (VEGFRs) [40]. Accumulated evidence suggests that merlin
can regulate RTK activity, possibly through their surface availabil-
ity and trafﬁcking and/or endocytosis [41]. In the schwannoma cell
line HEI193, overexpression of merlin inhibits proliferation
through accelerating PDGFR internalisation [42]. In primary
human schwannoma cells, PDGFRb is overexpressed and displays
a postponed and impaired degradation [33]. Merlin forms a com-
plex with PDGFR through Na+–H+ exchange regulatory cofactor
NHERF (also called EBP50), which plays a role in PDGFR internali-
sation and recycling. Merlin could also be involved in the late stage
of endocytosis by interacting with Hepatocyte Growth-factor
Receptor Substrate (HRS), which regulates endosomal trafﬁcking
of the membrane receptors including EGFR [43]. Therefore merlin
could play an important role in the process of PDGFR’s accumula-
tion, degradation and recycling. A similar mechanism is also dis-
cussed for other growth factor receptors, such as ErbB2 and 3,
and insulin-like growth factor 1 receptor [41]. In addition, inte-
grins, which are overexpressed in human schwannomas, could also
stabilize PDGFR and delay its degradation by enhancing its auto-
phosphorylation [44].
Ras/Raf/MEK/ERK and PI3K/AKT are two common pathways
downstream of RTKs in merlin-deﬁcient tumours. Schwannoma
cells display strong activation of MEK, ERK and AKT at basal level
or upon PDGF [33] and IGF stimulation (Ammoun et al., unpub-
lished data). In addition it has been demonstrated that merlin
inhibits PI3K activity by competing with PI3K for binding to PI3K
enhancer long form (PIKE-L) in HEK293 cells [45].
Co-operation between integrins and RTKs is important for cells
to control proliferation and survival [46]. In merlin-deﬁcient
tumours, RTK mediated signalling (mainly MAPK and PI3K/AKT)
is synergised with integrin mediated signalling (Rac/PAK/JNK and
FAK/Src). For example, the localisation of phospho-ERK1/2 can be
altered by inhibiting PAK with small molecule inhibitor IPA3 in
schwannoma cells [33] as PAK might function as a scaffold protein
for MAPK cascade. AKT is also placed downstream of PAK and FAK/
Src as both IPA3 and knock down of FAK downregulate the AKT
activity in human schwannoma cells (Ammoun et al., unpublished
data).
2.3. Contact inhibition and Wnt/b-catenin pathway
Loss of contact inhibition is part of the increased proliferation in
merlin-deﬁcient tumours. Potential mechanisms for this have been
investigated by analysing the relationship between merlin and
Rac/PAK, CD44, Paxillin, EGFR and other growth factor receptors
and cell density dependent regulation [21,39,42,47,48]. It has been
shown that merlin regulates adherens junctions (AJs) by forming a
complex with E/N-cadherin and b-catenin [49]. A recent study
demonstrated that Rac dependent Wnt/b-catenin signalling, which
was measured by the expression of Wnt target genes and TCF
activity, was found to be signiﬁcantly increased in NF2 knockout
mouse embryonic ﬁbroblasts in conﬂuent cell cultures [50]. In-
deed, a study in human schwannoma cells demonstrated degrada-
tion of adherens junctions and proliferative Wnt/b-catenin
signalling elevated as active b-catenin (dephosphorylated at serine
37 and threoine 41) localises to the nucleus and the Wnt targets
genes c-myc and cyclin D1 are upregulated in conﬂuent human
schwannoma cells [51]. Most importantly, the link between the
loss of the AJ complex and the increased proliferation in human
schwannoma cells is by RTK (PDGFR/Src) induced tyrosine 654
phosphorylation on b-catenin and dependent on integrin mediated
Rac/PAK/JNK pathway, as depletion of PAK2 suppressed active
b-catenin, c-myc, and cyclin D1. Therefore these studies suggest
a model that these pathways (including Wnt/b-catenin, RTKs and
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liferation in merlin-deﬁcient tumours.
3. In the nucleus, merlin suppresses ubiquitin E3 ligase activity
In addition to inhibiting mitogenic and survival signalling at or
near the cell cortex, active merlin also enters the nucleus to
suppresses the E3 ubiquitin ligase E3 CRLDCAF1 [52].
The strong direct interaction of merlin and the DDB1- and
CUL4-associated factor 1 (DCAF1) was identiﬁed by tandem afﬁnity
puriﬁcation followed by mass spectrometry. Studies have demon-
strated that DCAF1 functions as a substrate receptor for the Cul-
lin4-RING E3 ubiquitin ligase (CRL4) complex [53]. Interaction
analysis suggested that merlin wildtype but not NF2 patient-
derived merlin mutant (e.g. L64P), has a strong afﬁnity to the
CRL4DCAF1 complex. Immunoﬂuorescence studies indicate that
merlin in a dephosphorylated conformation has the ability to
shuttle into the nucleus and bind to CRL4DCAF1. Further genetic
experiments demonstrated that knock down of DCAF1 inhibits
the hyperproliferation in merlin-deﬁcient mesothelioma cells.
Importantly, we showed that, silencing of DCAF1 in NF2/ human
schwannoma cells suppressed the ability of these cells to progress
through G1 and to enter into S phase in response to mitogens. In
contrast, knockdown of DCAF1, did not signiﬁcantly affect the pro-
liferation of control human Schwann cells, where CRL4DCAF1 is not
disinhibited. It has been demonstrated that CRL4 ligase plays an
important role in genome stability, cell cycle regulation and his-
tone methylation [54]. Microarray data showed that depletion of
DCAF1 and re-expression of merlin induced similar changes in over
hundreds of genes [9], thus suggesting that merlin broadly regu-
lates gene expression by inhibiting CRL4DCAF1 activity. Taken to-
gether, these ﬁndings indicate that CRL4DCAF1 plays a key role in
NF2-dependent hyperproliferation and tumorigenesis in human
schwannomas and Merlin-deﬁcient tumours. Merlin, which is in
a non-phosphorylated status, enters into the nucleus to suppress
hyperproliferation by inhibiting CRL4DCAF1.
3.1. CRL4DCAF1 and the Hippo pathway
During organ development, cell number is strictly regulated. The
Hippo pathway controls organ size through restraining cell prolifer-
ation and promoting apoptosis in Drosophila and mammals [55].
The Hippo pathway also plays an important role in stem cell self-
renewal and tissue regeneration [56]. Many genes in the hippo
pathway are recognised as tumour suppressors as their mutations
are identiﬁed in human cancers including breast and liver cancer
[57,58]. The canonical Hippo pathway basically consists of a
three-tier kinase cascade: Hippo activates Warts, which in turn
phosphorylates Yorkie. The phosphorylation of Yorkie is critical
for its cytoplasmic localisation. The involvement of merlin in the
Hippo signalling pathway was initially revealed in Drosophila,
where merlin and another FERM domain protein Expanded act up-
stream of the Hippo pathway to inhibit cell proliferation and apop-
tosis [59,60]. Studies inmammalian cells also suggested thatmerlin
induces YAP (Yorkie Homologue) expression and localisation,
which is critical for the proliferation in merlin-deﬁcient mesotheli-
oma and meningioma cells [61,62]. A recent study suggested that
merlinmight work together with a newly identiﬁed Hippo pathway
component named Kibra to promote Lats1/2 (adaptor protein in the
Hippo pathway) phosphorylation in HEK293 cells [63]. Re-expres-
sion of merlin or inactivation of CRL4DCAF1 in mouse schwannoma
cells induces the expression of a subset of Hippo target genes [9].
A study in progress suggested that via a still unknown mechanism
merlin could regulate YAP phosphorylation, which is increased in
conﬂuent cells, through DCAF1 in the nucleus [64].3.2. Links between CRL4DCAF1 and membrane receptor signalling
In addition to the Hippo pathway discussed above, gene expres-
sion analysis demonstrated that depletion of DCAF1 or overexpres-
sion of merlin causes transcriptional alteration of main
components of integrin and RTKs pathways, (including itga6, itga7,
pdgfa and pdgfrb) as well as the genes jointly regulated by integrins
and RTKs (e.g. grb2 and cav1 [9]). Taken together, the mechanism
by which merlin exerts its inhibitory effects might involve a linked,
two-tier system. As shown in Fig. 1, as a tumour suppressor, merlin
seems to act in two linked signalling compartments: one at or close
to the membrane, mainly integrin and RTKs mediated or jointly
mediated signalling (including Ras/Raf/MEK/ERK, FAK/Src, PI3K/
AKT, mTORC1, Rac/PAK/JNK and Wnt/b-catenin); the other in the
nucleus, active merlin translocates into the nucleus to inhibit
CRL4DCAF1 ubiquitin E3 ligase activity. Importantly, the nuclear reg-
ulation of DCAF1 by merlin could enhance merlin’s function at the
membrane level by modifying the transcriptional level of integrins,
RTKs (especially PDFGR), and their downstream effectors. The com-
mon output of these pathways is to lead to increased proliferation
and survival.
4. Combination therapy and targeting ubiquitin E3 ligase
CRL4DCAF1
In addition to the disability from frequent merlin-related
spontaneous cancers, the inherited tumour syndrome NF2 with
multiple slow growing genetically well deﬁned tumours of the ner-
vous system leads to signiﬁcant medical problems, i.e. substantial
morbidity and reduced life span. Presently, the only treatment of
NF2 is surgery and radiosurgery, chemotherapy is not effective
due to the slow growth of NF2 related tumours. Surgery and radi-
osurgery are only locally effective and only treat a single tumour at
a time; furthermore these treatments can leave patients with
signiﬁcant morbidity. Thus, a new pharmaceutical treatment is
urgently required.
Current therapeutic strategies are focussing on targeting a sin-
gle pathway with speciﬁc small molecule inhibitors or monoclonal
antibodies mainly targeting RTK receptors. Indeed, EGFR/ErbB2 has
been targeted with Lapatinib in sporadic and NF2-related human
vestibular schwannomas [65–67]. A common RTK inhibitor, Niloti-
nib (targeting kinases PDGFR, BCR-ABL, and KIT), approved to treat
leukaemia and other cancers, was found to be effective in a
schwannoma in vitro model using primary tumour cells [68] and
is currently being tested in a phase 0 trial with NF2-schwannoma
patients. As angiogenesis has been detected in human vestibular
schwannomas, another strategy is to target VEGF, which plays an
important role in angiogenesis, with speciﬁc humanized antibody
(e.g. Bevacizumab). Indeed, improvement of hearing and reduction
of tumour growth has been found in a proportion of NF2 patients
after treated with Bevacizumab [69].
However as shown in Fig. 1 and summarised in a review by
Ammoun and Hanemann [40], merlin inhibits multiple pathways
at membrane level, therefore an inhibitor targeting multiple
targets might be needed to more effectively treat merlin-deﬁcient
tumours. Indeed a dual PDGFRb and Raf inhibitor, Sorafenib, re-
duced both basal and PDGF-mediated ERK1/2 and AKT activity
and decreased cell proliferation in human schwannoma cells
[33]. Sorafenib is currently being tested for NF2 patients in a phase
0 trial. The idea of combination therapy was supported by other
studies i.e. a dual inhibitor against mTORC1 and PI3K/AKT, such
as NVP-BEZ235 [70], was suggested by James et al. [36]. In addi-
tion, targeting a common molecule, which is downstream of sev-
eral pathways such as PI3K, could be a good strategy for the
treatment of NF2-related tumours [14].
Fig. 1. Merlin inhibits multiple co-operating signalling pathways at the membrane and nucleus. At the membrane, merlin inhibits (1) integrins mediating the Rac/PAK/JNK,
mTORC1, and FAK/Src pathways; (2) Receptor Tyrosine Kinases (RTKs) mediating Ras/Raf/MEK/ERK, PI3K/AKT, and (3) the Wnt/b-catenin pathways, which are also linked
with integrin and RTK mediated Rac/PAK/JNK signalling. FAK/Src plays a critical role because it connects the MAPK pathways and PI3K/AKT pathway. At the nucleus, Merlin
inhibits Cullin4-RING E3 ubiquitin ligase (CRL4) complex (including DDB1, Roc1) and E2 ligase through binding to the substrate receptor DCAF1. CRL4DCAF1 could also regulate
the expression of integrins and RTKs, therefore links to the membrane signalling. The common output of these pathways (upper and lower parts) is to lead to increased
proliferation and survival.
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are complex (Fig. 1), inhibition of a single growth factor receptor
or pathway may not suppress hyperproliferation of merlin-
deﬁcient tumours effectively; therefore a ‘‘master’’ therapeutic
target would be helpful. As discussed above, DCAF1 functions
upstream of RTKs/integrins/Hippo. Most importantly, depletion of
DCAF1 inhibits proliferation in schwannoma cells but not normal
Schwann cells. Thus, we hypothesis that CRL4DCAF1 is such a master
regulator.
Dysregulation of the ubiquitin pathway is associated with many
types of diseases, including cancer and neurodegenerative dis-
eases. The ubiquitin pathway is considered as a promising target
in cancer therapy [71]. The ubiquitin proteasome complex can be
targeted in multiple ways [72]. In the example of ubiquitination
of the tumour suppressor p53, E1 activity can be inhibited by a
cell-permeable inhibitor named PYR-41 [73], which induces apop-
tosis by increasing the expression levels and activity of p53. E3 and
substrate interactions can also be speciﬁcally blocked by a number
of peptide derivatives and small molecule inhibitors. For example,
nutlins (a family of cis-imidazoline analogues), RITA (reactivation
of p53 and induction of tumour cell apoptosis) and MI-63 had been
developed to block the binding of p53 and E3-ligase Mdm2 [74]
(murine double-minute clone 2, Hdm2 in human) speciﬁcally.
Treatment of various tumour cells with these inhibitors resulted
in accumulation of p53 and cell death [72,75]. Currently the ap-
proach to target E3 ligase activity closest to clinical application is
to inhibit proteasomes as many proteasome inhibitors have al-
ready been approved as effective anticancer drugs [76]. Because
CRL4DCAF1 could cause downstream proteasome dependent degra-
dation of substrates, e.g. uracil-DNA glycosylase-2 (UNG2) [77], it
is interesting to test whether proteasome pathways are involvedin the development of merlin-deﬁcient tumours. The research
compound MG132 is a cell-permeable tripeptide aldehyde and
has been widely used as a potent inhibitor to study the functions
of the ubiquitin proteasome pathways in mammalian cells. It has
been reported that MG132 could induce cell cycle arrest in RT4
rat schwannoma cells (14). Our data (Zhou & Hanemann, unpub-
lished) show that (1) human schwannoma cells treated for 24 h
with 1 lM MG132 returned to a normal Schwann-cell like bipolar
elongated shape, (2) the proliferation of schwannoma cells was
suppressed by MG132 treatments in a dose dependent manner
(3) the induction of cell-death in schwannoma cells was also ob-
served after 48 h treatment with 10 lMMG132. Those results sug-
gest that the merlin-related tumorigenesis is dependent, at least
partly, on the ubiquitin–proteasome system. In addition, protea-
some inhibitors may work on merlin-deﬁcient tumours by restora-
tion of phosphatase and tensin homologue (PTEN) expression,
which is downregulated in human schwannoma cells [14]. PTEN
functions as a negative regulator of PI3K signalling, which is one
of most important survival pathways in schwannoma and other
merlin-deﬁcient cells, therefore increase of PTEN level by protea-
some inhibitors will decrease PI3K signalling and lead to apoptosis.
However, there are potential shortcomings of targeting UPS
with non-speciﬁc proteasome inhibitors to treat merlin-deﬁcient
tumours. They could potentially result in stabilization of unwanted
proteins, e.g. an oncogene which could share a common E3 ligase
with a tumour suppressor. Commonly proteasome inhibitors pro-
mote apoptosis through by stabilising IjB then preventing activa-
tion of NFjB [78]. It has been shown that IjB shares a common E3
ligase SCFb-TrCP with b-catenin, which promotes proliferation in
merlin-deﬁcient tumours [51]. Further non-speciﬁc proteasome
inhibitors, such as Bortezomib, could cause side effects e.g.
L. Zhou, C.O. Hanemann / FEBS Letters 586 (2012) 1403–1408 1407peripheral neuropathy and gastrointestinal effects, that may be
due to targeting of the constitutive proteasome in these tissues
[79]. Therefore it is desirable to ﬁnd more speciﬁc approaches to
target CRL4DCAF1 for merlin-deﬁcient cells.
It has been demonstrated that the ubiquitination activity of
CRLs requires the covalent conjugation of an ubiquitin-like mole-
cule, NEDD8, onto the cullin component of CRLs, in a process called
neddylation. A speciﬁc CRL activity inhibitor, MLN4924, has
recently been described by Soucy et al. [80]. Inhibition of
NEDD8-activating enzyme (NAE) by MLN4924 leads to decreased
neddylation and inhibition of CRL activity. MLN4924 forms a cova-
lent adduct with NAE, which inhibits enzyme activity and thus pre-
vents ubiquitination and proteasomal degradation of CRL substrate
proteins [81]. MLN4924 induces apoptosis in tumour cells by
deregulation of S-phase DNA synthesis (MLN-treated cells dis-
played initiation of DNA synthesis but not transitioning into mito-
sis) and suppresses human HCT116 colon cancer and H522 lung
tumour xenografts in mice [80,82,83]. It has been demonstrated
that DCAF1 preferentially interacts with the NEDD8-modiﬁed form
of CUL4A [84], therefore there is potential to validate MLN4924 in
the treatment of Merlin-deﬁcient tumours. MLN4924 can sensitise
cancer cells but not normal cells to radiation [85], however, it has
been noticed that MLN4924 reduces Nedd8 activity in normal mice
[80]. Therefore to evaluate the effects of MLN4924, it is important
to determine whether MLN4924 has any impacts on merlin posi-
tive cells, such as Schwann cells.
5. Conclusions
Future studies that determine the substrates of CRL4DCAF1 will
help us to learn far more detail about the links between nuclear
and membrane signalling in merlin deﬁcient tumours. On the other
hand, it is also interesting to investigate existing feedback from the
membrane to the activation of CRLDCAF1 at the nuclear level in mer-
lin-deﬁcient cells. It is also crucial to ask whether merlin sup-
presses another ubiquitin E3 ligase at or near the membrane. The
answers to the above questions will certainly advance our under-
standing the biochemical functions of merlin and the mechanism
by which merlin suppresses tumorigenesis. Once we realise the
complex of the signalling pathway in merlin-deﬁcient tumours,
targeting a master/key regulator such as DCAF1, which rules both
the membrane and nuclear signalling, certainly will lead to a better
therapeutic strategy for the NF2 and other merlin-deﬁcient
patients.
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